Dr. William O’Neill: Impella for Cardiogenic Shock will be Major Advancement
In this Medpage Today video, Dr. William O'Neill of Detroit's Henry Ford Hospital explains why Impella will be a major advancement for the treatment of cardiogenic shock. His prognosis is based in part on his performed registry which found the survival of over 60% in patients that were treated very early. Dr. O'Neill's finding were used for FDA approval of the Impella device for cardiogenic shock. Tweet this, subscribe or find educational opportunities near you.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information